Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Moxifloxacin - Bayer

Next Previous
X
Search
Drug Profile

Moxifloxacin - Bayer

Alternative Names: Actira; Avalox; Avelox; Avelox IV; Avelox Oral; BAY 128039; Izilox; Megaxin; Moxibay; Moxifloxacine; Octegra; Proflox

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Class Antibacterials; Azabicyclo compounds; Cyclopropanes; Fluoroquinolones; Piperidines; Pyrrolidines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute exacerbations of chronic bronchitis; Acute sinusitis; Bacterial infections; Community-acquired pneumonia; Intra-abdominal infections; Pelvic inflammatory disorders; Plague; Respiratory tract infections; Skin and soft tissue infections
  • No development reported Tuberculosis

Most Recent Events

  • 01 Feb 2023 No development reported - Phase-III for Tuberculosis (Combination therapy) in Zambia, Thailand, Tanzania, Mexico, Kenya, Malaysia, India, China, South Africa (PO)
  • 17 Feb 2021 No development reported - Phase-III for Tuberculosis (Combination therapy) in Mozambique, Uganda, Philippines, Ukraine, Russia, Peru, Haiti, Georgia, Brazil (PO)
  • 01 May 2018 Global Alliance for TB Drug Development completes a phase III trial for Tuberculosis (Combination therapy) in Africa (including Mozambique, Zambia, Uganda, Kenya, South Africa and Tanzania), Asia (including Thailand, Philippines, Malaysia, China), Ukraine, Russia, Peru, Haiti, Georgia and Brazil (PO) (NCT02342886)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top